PDCD1 and melanoma: Indeed, therapies that control inhibitory pathways, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and/or programmed cell death protein-1 (PD-1) receptors, result in better outcomes for patients with advanced melanoma [4,5].